Evolus Inc
$ 6.66
-3.48%
29 Dec - close price
- Market Cap 447,257,000 USD
- Current Price $ 6.66
- High / Low $ 6.93 / 6.63
- Stock P/E N/A
- Book Value -0.44
- EPS -0.90
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.11 %
- ROE -187.30 %
- 52 Week High 17.12
- 52 Week Low 5.71
About
Evolus, Inc. is a pioneering aesthetic medical company based in Newport Beach, California, specializing in innovative beauty solutions tailored for healthcare providers and their patients. Its flagship offering, Jeuveau, is specifically formulated for the cosmetic market, underscoring the company's dedication to high-caliber aesthetic enhancements. With a strategic focus on product expansion and market penetration, Evolus is poised to capitalize on the growing demand within the aesthetic industry, positioning itself as a leader committed to transforming beauty standards and addressing the dynamic needs of consumers.
Analyst Target Price
$18.50
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-11 | 2025-08-05 | 2025-05-05 | 2025-03-04 | 2024-11-06 | 2024-07-31 | 2024-05-07 | 2024-03-07 | 2023-11-07 | 2023-08-02 | 2023-05-09 | 2023-03-08 |
| Reported EPS | -0.1478 | -0.27 | -0.17 | 0.0139 | -0.16 | -0.04 | -0.09 | -0.12 | -0.16 | -0.19 | -0.15 | -0.14 |
| Estimated EPS | -0.1467 | -0.1 | -0.1 | 0.0223 | -0.1 | -0.05 | -0.1 | -0.07 | -0.17 | -0.19 | -0.15 | -0.15 |
| Surprise | -0.0011 | -0.17 | -0.07 | -0.0084 | -0.06 | 0.01 | 0.01 | -0.05 | 0.01 | 0 | 0 | 0.01 |
| Surprise Percentage | -0.7498% | -170% | -70% | -37.6682% | -60% | 20% | 10% | -71.4286% | 5.8824% | 0% | 0% | 6.6667% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: EOLS
2025-12-24 22:09:28
Needham has reiterated a "Hold" recommendation for Evolus (EOLS). The average one-year price target for Evolus is $18.87/share, suggesting a 177.09% upside from its latest closing price of $6.81/share. Institutional ownership data shows varying activities among major holders like Nantahala Capital Management and Tang Capital Management.
2025-12-24 13:10:23
Needham & Company LLC has reaffirmed its "Hold" rating on Evolus (NASDAQ:EOLS), despite mixed analyst coverage that results in an average consensus of "Moderate Buy" with a $20.80 price target. The company's shares opened lower, trading at $6.81, significantly below its 1-year high. Evolus recently reported a narrower-than-expected loss but missed revenue estimates, and continues to show negative net margin and return on equity.
2025-12-24 11:10:23
Needham has reiterated a Hold rating for Evolus (EOLS) with no change to its price target, according to an update on December 24, 2025. This comes amidst varied analyst ratings and price target adjustments for Evolus in recent months, reflecting diverse perspectives on the company's market trajectory. Despite the varied ratings, the average target price from Wall Street analysts suggests a significant upside from the current stock price.
2025-12-20 04:40:00
This article presents an AI-driven analysis for Evolus Inc. (NASDAQ: EOLS), highlighting mixed sentiment and a mid-channel oscillation pattern. It outlines three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels, and provides multi-timeframe signal analysis for near, mid, and long-term horizons.
2025-12-17 15:09:17
Evolus, Inc. (NASDAQ:EOLS) has received a consensus "Moderate Buy" rating from brokerages, with an average one-year target price of $20.80. The company reported mixed quarterly results, beating EPS estimates but missing revenue expectations, and continues to operate at a loss. Institutional investors hold a significant portion of the stock, with some increasing their positions recently.
2025-12-15 23:10:00
Mizuho has lowered its price target for Evolus (EOLS) to $19 from $20, while maintaining an Outperform rating. This revision is due to waning consumer sentiment and inflationary pressures impacting demand for elective aesthetic procedures, despite Evolus's strong Q3 2025 performance and market share growth. The company's products, Jeuveau and Evolysse, face headwinds from a challenging US aesthetic market and a double-digit decline in the HA filler market.
